Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Arcofolin is a proprietary sodium salt of (6S)-5-methyltetrahydrofolic acid (5-MTHF), which is the primary biologically active form of folate found in human circulation. Developed by **Merck KGaA**, Arcofolin serves as a highly soluble and bioavailable alternative to synthetic folic acid. Unlike folic acid, which requires multi-step enzymatic reduction by dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) to become active, Arcofolin is immediately available for cellular utilization. This makes it particularly effective for individuals with MTHFR genetic polymorphisms who may have a reduced ability to process folic acid. It is utilized in dietary supplements, medical foods, and pharmaceutical formulations to address folate deficiency, support prenatal health (preventing neural tube defects), and manage conditions like hyperhomocysteinemia and depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Arcofolin.